nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefdinir—MPO—prostate cancer	0.625	1	CbGaD
Cefdinir—SLC22A5—Organic cation transport—SLC22A3—prostate cancer	0.00341	0.0516	CbGpPWpGaD
Cefdinir—SLC22A5—Organic cation transport—SLC22A1—prostate cancer	0.00278	0.0421	CbGpPWpGaD
Cefdinir—MPO—IL23-mediated signaling events—IL24—prostate cancer	0.00243	0.0368	CbGpPWpGaD
Cefdinir—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00231	0.035	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—ZFHX3—prostate cancer	0.00219	0.0333	CbGpPWpGaD
Cefdinir—SLC15A1—epithelium—prostate cancer	0.00214	0.0868	CbGeAlD
Cefdinir—MPO—Vitamin B12 Metabolism—SERPINA3—prostate cancer	0.00211	0.032	CbGpPWpGaD
Cefdinir—SLC15A1—renal system—prostate cancer	0.00199	0.0805	CbGeAlD
Cefdinir—MPO—epithelium—prostate cancer	0.00193	0.0781	CbGeAlD
Cefdinir—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00188	0.0285	CbGpPWpGaD
Cefdinir—SLC15A2—prostate gland—prostate cancer	0.00182	0.0739	CbGeAlD
Cefdinir—MPO—renal system—prostate cancer	0.00179	0.0725	CbGeAlD
Cefdinir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00172	0.0261	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—SERPINA3—prostate cancer	0.00171	0.026	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—RFK—prostate cancer	0.00161	0.0244	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—SEPP1—prostate cancer	0.0016	0.0243	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—VIMP—prostate cancer	0.0016	0.0243	CbGpPWpGaD
Cefdinir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00159	0.0242	CbGpPWpGaD
Cefdinir—SLC22A5—prostate gland—prostate cancer	0.00158	0.0642	CbGeAlD
Cefdinir—SLC15A2—seminal vesicle—prostate cancer	0.00154	0.0625	CbGeAlD
Cefdinir—MPO—Selenium Micronutrient Network—TXNRD2—prostate cancer	0.00147	0.0222	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—SERPINA3—prostate cancer	0.00136	0.0207	CbGpPWpGaD
Cefdinir—MPO—bone marrow—prostate cancer	0.00135	0.0548	CbGeAlD
Cefdinir—SLC22A5—seminal vesicle—prostate cancer	0.00134	0.0543	CbGeAlD
Cefdinir—MPO—Selenium Micronutrient Network—RFK—prostate cancer	0.00128	0.0194	CbGpPWpGaD
Cefdinir—SLC15A2—renal system—prostate cancer	0.00124	0.0503	CbGeAlD
Cefdinir—SLC15A2—urethra—prostate cancer	0.00122	0.0495	CbGeAlD
Cefdinir—MPO—Vitamin B12 Metabolism—TCN2—prostate cancer	0.00121	0.0184	CbGpPWpGaD
Cefdinir—MPO—testis—prostate cancer	0.00116	0.0468	CbGeAlD
Cefdinir—SLC22A5—renal system—prostate cancer	0.00108	0.0438	CbGeAlD
Cefdinir—Cefazolin—PON1—prostate cancer	0.00107	0.606	CrCbGaD
Cefdinir—SLC22A5—urethra—prostate cancer	0.00106	0.043	CbGeAlD
Cefdinir—MPO—Selenium Micronutrient Network—PRDX2—prostate cancer	0.00103	0.0157	CbGpPWpGaD
Cefdinir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.00101	0.0153	CbGpPWpGaD
Cefdinir—MPO—Vitamin B12 Metabolism—LRP2—prostate cancer	0.000987	0.015	CbGpPWpGaD
Cefdinir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.000939	0.0142	CbGpPWpGaD
Cefdinir—MPO—lymph node—prostate cancer	0.000837	0.0339	CbGeAlD
Cefdinir—SLC15A2—testis—prostate cancer	0.000803	0.0325	CbGeAlD
Cefdinir—MPO—C-MYB transcription factor network—CASP6—prostate cancer	0.000724	0.011	CbGpPWpGaD
Cefdinir—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000718	0.0109	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—GPX3—prostate cancer	0.000712	0.0108	CbGpPWpGaD
Cefdinir—SLC22A5—testis—prostate cancer	0.000698	0.0283	CbGeAlD
Cefdinir—MPO—IL23-mediated signaling events—IL18—prostate cancer	0.00066	0.01	CbGpPWpGaD
Cefdinir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000635	0.00963	CbGpPWpGaD
Cefdinir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000635	0.00963	CbGpPWpGaD
Cefdinir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.00059	0.00894	CbGpPWpGaD
Cefdinir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.00059	0.00894	CbGpPWpGaD
Cefdinir—SLC15A2—lymph node—prostate cancer	0.000582	0.0236	CbGeAlD
Cefdinir—MPO—C-MYB transcription factor network—MAD1L1—prostate cancer	0.000579	0.00877	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—GPX3—prostate cancer	0.000566	0.00858	CbGpPWpGaD
Cefdinir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.00052	0.00789	CbGpPWpGaD
Cefdinir—MPO—Vitamin B12 Metabolism—SOD2—prostate cancer	0.00051	0.00774	CbGpPWpGaD
Cefdinir—SLC22A5—lymph node—prostate cancer	0.000506	0.0205	CbGeAlD
Cefdinir—MPO—C-MYB transcription factor network—PPP3CA—prostate cancer	0.000499	0.00757	CbGpPWpGaD
Cefdinir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000483	0.00732	CbGpPWpGaD
Cefdinir—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000463	0.00701	CbGpPWpGaD
Cefdinir—SLC15A2—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000452	0.00686	CbGpPWpGaD
Cefdinir—MPO—Vitamin B12 Metabolism—MTHFR—prostate cancer	0.000449	0.00681	CbGpPWpGaD
Cefdinir—Cefaclor—MPO—prostate cancer	0.000433	0.246	CrCbGaD
Cefdinir—SLC15A1—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.00042	0.00636	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—SOD2—prostate cancer	0.000415	0.0063	CbGpPWpGaD
Cefdinir—SLC22A5—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000413	0.00626	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—MAP3K7—prostate cancer	0.000406	0.00615	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—GGT1—prostate cancer	0.000398	0.00604	CbGpPWpGaD
Cefdinir—MPO—IL23-mediated signaling events—JAK2—prostate cancer	0.000394	0.00597	CbGpPWpGaD
Cefdinir—MPO—Vitamin B12 Metabolism—ICAM1—prostate cancer	0.000393	0.00596	CbGpPWpGaD
Cefdinir—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000377	0.00572	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—MTHFR—prostate cancer	0.000366	0.00554	CbGpPWpGaD
Cefdinir—SLC15A2—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000357	0.00542	CbGpPWpGaD
Cefdinir—MPO—Vitamin B12 Metabolism—INS—prostate cancer	0.000357	0.00542	CbGpPWpGaD
Cefdinir—MPO—IL23-mediated signaling events—IL2—prostate cancer	0.000343	0.00521	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—GSTM1—prostate cancer	0.000341	0.00517	CbGpPWpGaD
Cefdinir—SLC15A1—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000332	0.00503	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—SOD2—prostate cancer	0.00033	0.005	CbGpPWpGaD
Cefdinir—MPO—Vitamin B12 Metabolism—SERPINE1—prostate cancer	0.000328	0.00498	CbGpPWpGaD
Cefdinir—SLC22A5—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000326	0.00495	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—ICAM1—prostate cancer	0.00032	0.00485	CbGpPWpGaD
Cefdinir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000306	0.00465	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—INS—prostate cancer	0.000291	0.00441	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—MTHFR—prostate cancer	0.00029	0.0044	CbGpPWpGaD
Cefdinir—MPO—IL23-mediated signaling events—STAT3—prostate cancer	0.000289	0.00438	CbGpPWpGaD
Cefdinir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000284	0.00431	CbGpPWpGaD
Cefdinir—SLC15A2—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000284	0.0043	CbGpPWpGaD
Cefdinir—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000284	0.0043	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—SERPINE1—prostate cancer	0.000267	0.00405	CbGpPWpGaD
Cefdinir—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000263	0.004	CbGpPWpGaD
Cefdinir—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000263	0.004	CbGpPWpGaD
Cefdinir—SLC22A5—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000259	0.00393	CbGpPWpGaD
Cefdinir—SLC22A5—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000259	0.00393	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—ICAM1—prostate cancer	0.000254	0.00385	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—CREBBP—prostate cancer	0.000235	0.00356	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—INS—prostate cancer	0.000231	0.0035	CbGpPWpGaD
Cefdinir—SLC15A2—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00023	0.00349	CbGpPWpGaD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.00023	0.00348	CbGpPWpGaD
Cefdinir—MPO—IL23-mediated signaling events—PIK3CA—prostate cancer	0.000228	0.00346	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—IL2—prostate cancer	0.000216	0.00328	CbGpPWpGaD
Cefdinir—SLC15A1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000214	0.00324	CbGpPWpGaD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000213	0.00323	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—SERPINE1—prostate cancer	0.000212	0.00322	CbGpPWpGaD
Cefdinir—SLC22A5—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00021	0.00319	CbGpPWpGaD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.00021	0.00318	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—BCL2—prostate cancer	0.000202	0.00307	CbGpPWpGaD
Cefdinir—MPO—IL23-mediated signaling events—IL6—prostate cancer	0.000202	0.00306	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—PTGS2—prostate cancer	0.000192	0.00292	CbGpPWpGaD
Cefdinir—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000188	0.00285	CbGpPWpGaD
Cefdinir—MPO—Selenium Micronutrient Network—PTGS2—prostate cancer	0.000185	0.00281	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—CDKN1B—prostate cancer	0.000182	0.00276	CbGpPWpGaD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000182	0.00275	CbGpPWpGaD
Cefdinir—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000174	0.00264	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—CCND1—prostate cancer	0.000174	0.00263	CbGpPWpGaD
Cefdinir—SLC22A5—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000171	0.0026	CbGpPWpGaD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000169	0.00256	CbGpPWpGaD
Cefdinir—MPO—C-MYB transcription factor network—CDKN1A—prostate cancer	0.000168	0.00255	CbGpPWpGaD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000166	0.00251	CbGpPWpGaD
Cefdinir—Renal impairment—Doxorubicin—prostate cancer	0.000161	0.00057	CcSEcCtD
Cefdinir—Acute coronary syndrome—Prednisone—prostate cancer	0.000161	0.00057	CcSEcCtD
Cefdinir—Erythema multiforme—Docetaxel—prostate cancer	0.000161	0.000569	CcSEcCtD
Cefdinir—Constipation—Estradiol—prostate cancer	0.00016	0.000567	CcSEcCtD
Cefdinir—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00016	0.000567	CcSEcCtD
Cefdinir—MPO—C-MYB transcription factor network—EP300—prostate cancer	0.00016	0.00242	CbGpPWpGaD
Cefdinir—Myocardial infarction—Prednisone—prostate cancer	0.00016	0.000566	CcSEcCtD
Cefdinir—Leukopenia—Etoposide—prostate cancer	0.000159	0.000564	CcSEcCtD
Cefdinir—Cefradine—CYP3A4—prostate cancer	0.000159	0.0902	CrCbGaD
Cefdinir—Purpura—Doxorubicin—prostate cancer	0.000159	0.000563	CcSEcCtD
Cefdinir—Cardiac failure—Doxorubicin—prostate cancer	0.000157	0.000556	CcSEcCtD
Cefdinir—Loss of consciousness—Etoposide—prostate cancer	0.000156	0.000554	CcSEcCtD
Cefdinir—Dizziness—Goserelin—prostate cancer	0.000156	0.000553	CcSEcCtD
Cefdinir—MPO—Vitamin B12 Metabolism—IL6—prostate cancer	0.000156	0.00237	CbGpPWpGaD
Cefdinir—Erythema multiforme—Capecitabine—prostate cancer	0.000155	0.000551	CcSEcCtD
Cefdinir—Somnolence—Mitoxantrone—prostate cancer	0.000155	0.00055	CcSEcCtD
Cefdinir—Dizziness—Conjugated Estrogens—prostate cancer	0.000155	0.000548	CcSEcCtD
Cefdinir—Convulsion—Etoposide—prostate cancer	0.000154	0.000546	CcSEcCtD
Cefdinir—Dyspepsia—Mitoxantrone—prostate cancer	0.000154	0.000544	CcSEcCtD
Cefdinir—Hypertension—Etoposide—prostate cancer	0.000154	0.000544	CcSEcCtD
Cefdinir—Gastrointestinal pain—Estradiol—prostate cancer	0.000153	0.000543	CcSEcCtD
Cefdinir—Decreased appetite—Mitoxantrone—prostate cancer	0.000152	0.000537	CcSEcCtD
Cefdinir—Chest pain—Etoposide—prostate cancer	0.000151	0.000536	CcSEcCtD
Cefdinir—Vomiting—Goserelin—prostate cancer	0.00015	0.000532	CcSEcCtD
Cefdinir—Constipation—Mitoxantrone—prostate cancer	0.000149	0.000529	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.000149	0.000528	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000149	0.000528	CcSEcCtD
Cefdinir—Rash—Goserelin—prostate cancer	0.000149	0.000528	CcSEcCtD
Cefdinir—Dermatitis—Goserelin—prostate cancer	0.000149	0.000527	CcSEcCtD
Cefdinir—Vomiting—Conjugated Estrogens—prostate cancer	0.000149	0.000527	CcSEcCtD
Cefdinir—Body temperature increased—Estradiol—prostate cancer	0.000148	0.000525	CcSEcCtD
Cefdinir—Abdominal pain—Estradiol—prostate cancer	0.000148	0.000525	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000148	0.00224	CbGpPWpGaD
Cefdinir—Headache—Goserelin—prostate cancer	0.000148	0.000524	CcSEcCtD
Cefdinir—Rash—Conjugated Estrogens—prostate cancer	0.000148	0.000523	CcSEcCtD
Cefdinir—Dermatitis—Conjugated Estrogens—prostate cancer	0.000147	0.000522	CcSEcCtD
Cefdinir—Haemoglobin—Prednisone—prostate cancer	0.000147	0.000521	CcSEcCtD
Cefdinir—Headache—Conjugated Estrogens—prostate cancer	0.000147	0.000519	CcSEcCtD
Cefdinir—Haemorrhage—Prednisone—prostate cancer	0.000146	0.000519	CcSEcCtD
Cefdinir—Anaphylactic shock—Etoposide—prostate cancer	0.000145	0.000514	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000144	0.00219	CbGpPWpGaD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000144	0.00219	CbGpPWpGaD
Cefdinir—Asthma—Epirubicin—prostate cancer	0.000143	0.000507	CcSEcCtD
Cefdinir—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000143	0.000506	CcSEcCtD
Cefdinir—Thrombocytopenia—Etoposide—prostate cancer	0.000142	0.000504	CcSEcCtD
Cefdinir—Flatulence—Capecitabine—prostate cancer	0.000141	0.0005	CcSEcCtD
Cefdinir—Nausea—Goserelin—prostate cancer	0.00014	0.000497	CcSEcCtD
Cefdinir—MPO—C-MYB transcription factor network—MYC—prostate cancer	0.000139	0.00211	CbGpPWpGaD
Cefdinir—Nausea—Conjugated Estrogens—prostate cancer	0.000139	0.000492	CcSEcCtD
Cefdinir—MPO—Folate Metabolism—TP53—prostate cancer	0.000139	0.0021	CbGpPWpGaD
Cefdinir—Anorexia—Etoposide—prostate cancer	0.000138	0.00049	CcSEcCtD
Cefdinir—Hypersensitivity—Estradiol—prostate cancer	0.000138	0.000489	CcSEcCtD
Cefdinir—Abdominal pain—Mitoxantrone—prostate cancer	0.000138	0.000489	CcSEcCtD
Cefdinir—Body temperature increased—Mitoxantrone—prostate cancer	0.000138	0.000489	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	0.000138	0.000489	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000138	0.000489	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000137	0.00208	CbGpPWpGaD
Cefdinir—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000137	0.00208	CbGpPWpGaD
Cefdinir—Pancytopenia—Epirubicin—prostate cancer	0.000136	0.000481	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000135	0.00205	CbGpPWpGaD
Cefdinir—Asthenia—Estradiol—prostate cancer	0.000134	0.000476	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000134	0.00203	CbGpPWpGaD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000134	0.00203	CbGpPWpGaD
Cefdinir—Neutropenia—Epirubicin—prostate cancer	0.000134	0.000474	CcSEcCtD
Cefdinir—Pruritus—Estradiol—prostate cancer	0.000133	0.000469	CcSEcCtD
Cefdinir—Asthma—Doxorubicin—prostate cancer	0.000132	0.000469	CcSEcCtD
Cefdinir—Leukopenia—Docetaxel—prostate cancer	0.000132	0.000469	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000132	0.002	CbGpPWpGaD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000132	0.002	CbGpPWpGaD
Cefdinir—Loss of consciousness—Docetaxel—prostate cancer	0.00013	0.00046	CcSEcCtD
Cefdinir—Somnolence—Etoposide—prostate cancer	0.000129	0.000457	CcSEcCtD
Cefdinir—MPO—C-MYB transcription factor network—KRAS—prostate cancer	0.000129	0.00195	CbGpPWpGaD
Cefdinir—Hypersensitivity—Mitoxantrone—prostate cancer	0.000129	0.000455	CcSEcCtD
Cefdinir—Pneumonia—Epirubicin—prostate cancer	0.000128	0.000455	CcSEcCtD
Cefdinir—Diarrhoea—Estradiol—prostate cancer	0.000128	0.000454	CcSEcCtD
Cefdinir—Leukopenia—Capecitabine—prostate cancer	0.000128	0.000454	CcSEcCtD
Cefdinir—Convulsion—Docetaxel—prostate cancer	0.000128	0.000454	CcSEcCtD
Cefdinir—Hypertension—Docetaxel—prostate cancer	0.000128	0.000452	CcSEcCtD
Cefdinir—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000127	0.00193	CbGpPWpGaD
Cefdinir—MPO—Folate Metabolism—IL6—prostate cancer	0.000127	0.00193	CbGpPWpGaD
Cefdinir—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000126	0.000448	CcSEcCtD
Cefdinir—Decreased appetite—Etoposide—prostate cancer	0.000126	0.000447	CcSEcCtD
Cefdinir—Chest pain—Docetaxel—prostate cancer	0.000126	0.000446	CcSEcCtD
Cefdinir—Loss of consciousness—Capecitabine—prostate cancer	0.000126	0.000446	CcSEcCtD
Cefdinir—Pancytopenia—Doxorubicin—prostate cancer	0.000126	0.000445	CcSEcCtD
Cefdinir—Renal failure—Epirubicin—prostate cancer	0.000125	0.000444	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Etoposide—prostate cancer	0.000125	0.000444	CcSEcCtD
Cefdinir—Asthenia—Mitoxantrone—prostate cancer	0.000125	0.000444	CcSEcCtD
Cefdinir—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000125	0.0019	CbGpPWpGaD
Cefdinir—Jaundice—Epirubicin—prostate cancer	0.000124	0.000441	CcSEcCtD
Cefdinir—Stomatitis—Epirubicin—prostate cancer	0.000124	0.000441	CcSEcCtD
Cefdinir—Constipation—Etoposide—prostate cancer	0.000124	0.00044	CcSEcCtD
Cefdinir—Conjunctivitis—Epirubicin—prostate cancer	0.000124	0.000439	CcSEcCtD
Cefdinir—Dizziness—Estradiol—prostate cancer	0.000124	0.000439	CcSEcCtD
Cefdinir—Neutropenia—Doxorubicin—prostate cancer	0.000124	0.000439	CcSEcCtD
Cefdinir—Hypertension—Capecitabine—prostate cancer	0.000124	0.000438	CcSEcCtD
Cefdinir—Dry mouth—Docetaxel—prostate cancer	0.000123	0.000436	CcSEcCtD
Cefdinir—Chest pain—Capecitabine—prostate cancer	0.000122	0.000432	CcSEcCtD
Cefdinir—Haematuria—Epirubicin—prostate cancer	0.000122	0.000431	CcSEcCtD
Cefdinir—Anaphylactic shock—Docetaxel—prostate cancer	0.000121	0.000427	CcSEcCtD
Cefdinir—Diarrhoea—Mitoxantrone—prostate cancer	0.000119	0.000423	CcSEcCtD
Cefdinir—Dry mouth—Capecitabine—prostate cancer	0.000119	0.000422	CcSEcCtD
Cefdinir—Vomiting—Estradiol—prostate cancer	0.000119	0.000422	CcSEcCtD
Cefdinir—Agranulocytosis—Epirubicin—prostate cancer	0.000119	0.000422	CcSEcCtD
Cefdinir—Pneumonia—Doxorubicin—prostate cancer	0.000119	0.000421	CcSEcCtD
Cefdinir—Gastrointestinal pain—Etoposide—prostate cancer	0.000119	0.000421	CcSEcCtD
Cefdinir—Shock—Docetaxel—prostate cancer	0.000119	0.00042	CcSEcCtD
Cefdinir—Thrombocytopenia—Docetaxel—prostate cancer	0.000118	0.000418	CcSEcCtD
Cefdinir—Rash—Estradiol—prostate cancer	0.000118	0.000418	CcSEcCtD
Cefdinir—Dermatitis—Estradiol—prostate cancer	0.000118	0.000418	CcSEcCtD
Cefdinir—Headache—Estradiol—prostate cancer	0.000117	0.000416	CcSEcCtD
Cefdinir—Agitation—Prednisone—prostate cancer	0.000117	0.000415	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000117	0.000415	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000117	0.00177	CbGpPWpGaD
Cefdinir—Renal failure—Doxorubicin—prostate cancer	0.000116	0.000411	CcSEcCtD
Cefdinir—Haemoglobin—Epirubicin—prostate cancer	0.000115	0.000408	CcSEcCtD
Cefdinir—Stomatitis—Doxorubicin—prostate cancer	0.000115	0.000408	CcSEcCtD
Cefdinir—Jaundice—Doxorubicin—prostate cancer	0.000115	0.000408	CcSEcCtD
Cefdinir—Anorexia—Docetaxel—prostate cancer	0.000115	0.000407	CcSEcCtD
Cefdinir—Shock—Capecitabine—prostate cancer	0.000115	0.000407	CcSEcCtD
Cefdinir—Abdominal pain—Etoposide—prostate cancer	0.000115	0.000407	CcSEcCtD
Cefdinir—Body temperature increased—Etoposide—prostate cancer	0.000115	0.000407	CcSEcCtD
Cefdinir—Conjunctivitis—Doxorubicin—prostate cancer	0.000115	0.000407	CcSEcCtD
Cefdinir—Haemorrhage—Epirubicin—prostate cancer	0.000115	0.000406	CcSEcCtD
Cefdinir—Thrombocytopenia—Capecitabine—prostate cancer	0.000114	0.000405	CcSEcCtD
Cefdinir—Haematuria—Doxorubicin—prostate cancer	0.000113	0.000399	CcSEcCtD
Cefdinir—Loss of consciousness—Prednisone—prostate cancer	0.000112	0.000397	CcSEcCtD
Cefdinir—Anorexia—Capecitabine—prostate cancer	0.000111	0.000394	CcSEcCtD
Cefdinir—Nausea—Estradiol—prostate cancer	0.000111	0.000394	CcSEcCtD
Cefdinir—Vomiting—Mitoxantrone—prostate cancer	0.000111	0.000393	CcSEcCtD
Cefdinir—Convulsion—Prednisone—prostate cancer	0.00011	0.000391	CcSEcCtD
Cefdinir—Agranulocytosis—Doxorubicin—prostate cancer	0.00011	0.00039	CcSEcCtD
Cefdinir—Hypertension—Prednisone—prostate cancer	0.00011	0.00039	CcSEcCtD
Cefdinir—Rash—Mitoxantrone—prostate cancer	0.00011	0.00039	CcSEcCtD
Cefdinir—Dermatitis—Mitoxantrone—prostate cancer	0.00011	0.000389	CcSEcCtD
Cefdinir—Headache—Mitoxantrone—prostate cancer	0.000109	0.000387	CcSEcCtD
Cefdinir—Insomnia—Docetaxel—prostate cancer	0.000109	0.000387	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000109	0.00165	CbGpPWpGaD
Cefdinir—Erythema multiforme—Epirubicin—prostate cancer	0.000108	0.000384	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000108	0.00164	CbGpPWpGaD
Cefdinir—Somnolence—Docetaxel—prostate cancer	0.000107	0.00038	CcSEcCtD
Cefdinir—Hypersensitivity—Etoposide—prostate cancer	0.000107	0.000379	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000107	0.00162	CbGpPWpGaD
Cefdinir—Haemoglobin—Doxorubicin—prostate cancer	0.000107	0.000377	CcSEcCtD
Cefdinir—Dyspepsia—Docetaxel—prostate cancer	0.000106	0.000376	CcSEcCtD
Cefdinir—Haemorrhage—Doxorubicin—prostate cancer	0.000106	0.000375	CcSEcCtD
Cefdinir—Insomnia—Capecitabine—prostate cancer	0.000106	0.000374	CcSEcCtD
Cefdinir—Decreased appetite—Docetaxel—prostate cancer	0.000105	0.000372	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000104	0.000369	CcSEcCtD
Cefdinir—Asthenia—Etoposide—prostate cancer	0.000104	0.000369	CcSEcCtD
Cefdinir—Anaphylactic shock—Prednisone—prostate cancer	0.000104	0.000369	CcSEcCtD
Cefdinir—Nausea—Mitoxantrone—prostate cancer	0.000104	0.000367	CcSEcCtD
Cefdinir—Constipation—Docetaxel—prostate cancer	0.000103	0.000365	CcSEcCtD
Cefdinir—Cephalexin—CYP3A4—prostate cancer	0.000103	0.0584	CrCbGaD
Cefdinir—Dyspepsia—Capecitabine—prostate cancer	0.000103	0.000364	CcSEcCtD
Cefdinir—Pruritus—Etoposide—prostate cancer	0.000103	0.000364	CcSEcCtD
Cefdinir—Shock—Prednisone—prostate cancer	0.000102	0.000363	CcSEcCtD
Cefdinir—Decreased appetite—Capecitabine—prostate cancer	0.000102	0.00036	CcSEcCtD
Cefdinir—MPO—Selenium Micronutrient Network—IL6—prostate cancer	0.000101	0.00153	CbGpPWpGaD
Cefdinir—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000101	0.000357	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.0001	0.00152	CbGpPWpGaD
Cefdinir—Erythema multiforme—Doxorubicin—prostate cancer	0.0001	0.000355	CcSEcCtD
Cefdinir—Constipation—Capecitabine—prostate cancer	9.99e-05	0.000354	CcSEcCtD
Cefdinir—Diarrhoea—Etoposide—prostate cancer	9.93e-05	0.000352	CcSEcCtD
Cefdinir—Anorexia—Prednisone—prostate cancer	9.92e-05	0.000351	CcSEcCtD
Cefdinir—Gastrointestinal pain—Docetaxel—prostate cancer	9.86e-05	0.000349	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—ABCG5—prostate cancer	9.86e-05	0.00149	CbGpPWpGaD
Cefdinir—Flatulence—Epirubicin—prostate cancer	9.82e-05	0.000348	CcSEcCtD
Cefdinir—Dizziness—Etoposide—prostate cancer	9.6e-05	0.00034	CcSEcCtD
Cefdinir—Gastrointestinal pain—Capecitabine—prostate cancer	9.55e-05	0.000338	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	9.54e-05	0.00145	CbGpPWpGaD
Cefdinir—Abdominal pain—Docetaxel—prostate cancer	9.54e-05	0.000338	CcSEcCtD
Cefdinir—Body temperature increased—Docetaxel—prostate cancer	9.54e-05	0.000338	CcSEcCtD
Cefdinir—Insomnia—Prednisone—prostate cancer	9.41e-05	0.000333	CcSEcCtD
Cefdinir—Abdominal pain—Capecitabine—prostate cancer	9.23e-05	0.000327	CcSEcCtD
Cefdinir—Body temperature increased—Capecitabine—prostate cancer	9.23e-05	0.000327	CcSEcCtD
Cefdinir—Vomiting—Etoposide—prostate cancer	9.23e-05	0.000327	CcSEcCtD
Cefdinir—Agitation—Epirubicin—prostate cancer	9.16e-05	0.000325	CcSEcCtD
Cefdinir—Dyspepsia—Prednisone—prostate cancer	9.16e-05	0.000324	CcSEcCtD
Cefdinir—Rash—Etoposide—prostate cancer	9.15e-05	0.000324	CcSEcCtD
Cefdinir—Dermatitis—Etoposide—prostate cancer	9.14e-05	0.000324	CcSEcCtD
Cefdinir—Headache—Etoposide—prostate cancer	9.09e-05	0.000322	CcSEcCtD
Cefdinir—Flatulence—Doxorubicin—prostate cancer	9.09e-05	0.000322	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—GNG5—prostate cancer	9.07e-05	0.00138	CbGpPWpGaD
Cefdinir—Decreased appetite—Prednisone—prostate cancer	9.04e-05	0.00032	CcSEcCtD
Cefdinir—Leukopenia—Epirubicin—prostate cancer	8.92e-05	0.000316	CcSEcCtD
Cefdinir—Constipation—Prednisone—prostate cancer	8.9e-05	0.000315	CcSEcCtD
Cefdinir—Hypersensitivity—Docetaxel—prostate cancer	8.89e-05	0.000315	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	8.85e-05	0.00134	CbGpPWpGaD
Cefdinir—Loss of consciousness—Epirubicin—prostate cancer	8.76e-05	0.00031	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—SLC22A1—prostate cancer	8.71e-05	0.00132	CbGpPWpGaD
Cefdinir—Asthenia—Docetaxel—prostate cancer	8.66e-05	0.000307	CcSEcCtD
Cefdinir—Convulsion—Epirubicin—prostate cancer	8.64e-05	0.000306	CcSEcCtD
Cefdinir—Nausea—Etoposide—prostate cancer	8.62e-05	0.000305	CcSEcCtD
Cefdinir—Hypertension—Epirubicin—prostate cancer	8.61e-05	0.000305	CcSEcCtD
Cefdinir—Hypersensitivity—Capecitabine—prostate cancer	8.61e-05	0.000305	CcSEcCtD
Cefdinir—Pruritus—Docetaxel—prostate cancer	8.53e-05	0.000302	CcSEcCtD
Cefdinir—Gastrointestinal pain—Prednisone—prostate cancer	8.51e-05	0.000301	CcSEcCtD
Cefdinir—Chest pain—Epirubicin—prostate cancer	8.49e-05	0.000301	CcSEcCtD
Cefdinir—Agitation—Doxorubicin—prostate cancer	8.48e-05	0.0003	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—GNG5—prostate cancer	8.42e-05	0.00128	CbGpPWpGaD
Cefdinir—Asthenia—Capecitabine—prostate cancer	8.38e-05	0.000297	CcSEcCtD
Cefdinir—Dry mouth—Epirubicin—prostate cancer	8.3e-05	0.000294	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—GNG5—prostate cancer	8.28e-05	0.00126	CbGpPWpGaD
Cefdinir—Pruritus—Capecitabine—prostate cancer	8.26e-05	0.000293	CcSEcCtD
Cefdinir—Leukopenia—Doxorubicin—prostate cancer	8.26e-05	0.000293	CcSEcCtD
Cefdinir—Diarrhoea—Docetaxel—prostate cancer	8.25e-05	0.000292	CcSEcCtD
Cefdinir—Abdominal pain—Prednisone—prostate cancer	8.22e-05	0.000291	CcSEcCtD
Cefdinir—Body temperature increased—Prednisone—prostate cancer	8.22e-05	0.000291	CcSEcCtD
Cefdinir—Anaphylactic shock—Epirubicin—prostate cancer	8.14e-05	0.000288	CcSEcCtD
Cefdinir—Loss of consciousness—Doxorubicin—prostate cancer	8.11e-05	0.000287	CcSEcCtD
Cefdinir—Shock—Epirubicin—prostate cancer	8.01e-05	0.000284	CcSEcCtD
Cefdinir—Convulsion—Doxorubicin—prostate cancer	7.99e-05	0.000283	CcSEcCtD
Cefdinir—Diarrhoea—Capecitabine—prostate cancer	7.99e-05	0.000283	CcSEcCtD
Cefdinir—Dizziness—Docetaxel—prostate cancer	7.98e-05	0.000283	CcSEcCtD
Cefdinir—Thrombocytopenia—Epirubicin—prostate cancer	7.97e-05	0.000282	CcSEcCtD
Cefdinir—Hypertension—Doxorubicin—prostate cancer	7.96e-05	0.000282	CcSEcCtD
Cefdinir—Chest pain—Doxorubicin—prostate cancer	7.85e-05	0.000278	CcSEcCtD
Cefdinir—Anorexia—Epirubicin—prostate cancer	7.76e-05	0.000275	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	7.74e-05	0.00117	CbGpPWpGaD
Cefdinir—Dizziness—Capecitabine—prostate cancer	7.72e-05	0.000274	CcSEcCtD
Cefdinir—Dry mouth—Doxorubicin—prostate cancer	7.68e-05	0.000272	CcSEcCtD
Cefdinir—Vomiting—Docetaxel—prostate cancer	7.67e-05	0.000272	CcSEcCtD
Cefdinir—Hypersensitivity—Prednisone—prostate cancer	7.67e-05	0.000272	CcSEcCtD
Cefdinir—Rash—Docetaxel—prostate cancer	7.61e-05	0.000269	CcSEcCtD
Cefdinir—Dermatitis—Docetaxel—prostate cancer	7.6e-05	0.000269	CcSEcCtD
Cefdinir—Headache—Docetaxel—prostate cancer	7.56e-05	0.000268	CcSEcCtD
Cefdinir—Anaphylactic shock—Doxorubicin—prostate cancer	7.53e-05	0.000267	CcSEcCtD
Cefdinir—Asthenia—Prednisone—prostate cancer	7.46e-05	0.000264	CcSEcCtD
Cefdinir—Vomiting—Capecitabine—prostate cancer	7.43e-05	0.000263	CcSEcCtD
Cefdinir—Shock—Doxorubicin—prostate cancer	7.41e-05	0.000262	CcSEcCtD
Cefdinir—Thrombocytopenia—Doxorubicin—prostate cancer	7.37e-05	0.000261	CcSEcCtD
Cefdinir—Rash—Capecitabine—prostate cancer	7.36e-05	0.000261	CcSEcCtD
Cefdinir—Pruritus—Prednisone—prostate cancer	7.36e-05	0.000261	CcSEcCtD
Cefdinir—Insomnia—Epirubicin—prostate cancer	7.36e-05	0.000261	CcSEcCtD
Cefdinir—Dermatitis—Capecitabine—prostate cancer	7.36e-05	0.000261	CcSEcCtD
Cefdinir—Headache—Capecitabine—prostate cancer	7.32e-05	0.000259	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	7.3e-05	0.00111	CbGpPWpGaD
Cefdinir—Somnolence—Epirubicin—prostate cancer	7.23e-05	0.000256	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	7.18e-05	0.00109	CbGpPWpGaD
Cefdinir—Anorexia—Doxorubicin—prostate cancer	7.18e-05	0.000254	CcSEcCtD
Cefdinir—Nausea—Docetaxel—prostate cancer	7.17e-05	0.000254	CcSEcCtD
Cefdinir—Dyspepsia—Epirubicin—prostate cancer	7.16e-05	0.000254	CcSEcCtD
Cefdinir—Diarrhoea—Prednisone—prostate cancer	7.12e-05	0.000252	CcSEcCtD
Cefdinir—Decreased appetite—Epirubicin—prostate cancer	7.07e-05	0.000251	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—PRKACB—prostate cancer	7.06e-05	0.00107	CbGpPWpGaD
Cefdinir—Gastrointestinal disorder—Epirubicin—prostate cancer	7.02e-05	0.000249	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.96e-05	0.00106	CbGpPWpGaD
Cefdinir—Constipation—Epirubicin—prostate cancer	6.96e-05	0.000247	CcSEcCtD
Cefdinir—Nausea—Capecitabine—prostate cancer	6.94e-05	0.000246	CcSEcCtD
Cefdinir—Dizziness—Prednisone—prostate cancer	6.88e-05	0.000244	CcSEcCtD
Cefdinir—Insomnia—Doxorubicin—prostate cancer	6.81e-05	0.000241	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	6.77e-05	0.00103	CbGpPWpGaD
Cefdinir—Somnolence—Doxorubicin—prostate cancer	6.69e-05	0.000237	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—NCOA2—prostate cancer	6.66e-05	0.00101	CbGpPWpGaD
Cefdinir—Gastrointestinal pain—Epirubicin—prostate cancer	6.65e-05	0.000236	CcSEcCtD
Cefdinir—Dyspepsia—Doxorubicin—prostate cancer	6.63e-05	0.000235	CcSEcCtD
Cefdinir—Vomiting—Prednisone—prostate cancer	6.61e-05	0.000234	CcSEcCtD
Cefdinir—Rash—Prednisone—prostate cancer	6.56e-05	0.000232	CcSEcCtD
Cefdinir—Dermatitis—Prednisone—prostate cancer	6.55e-05	0.000232	CcSEcCtD
Cefdinir—Decreased appetite—Doxorubicin—prostate cancer	6.54e-05	0.000232	CcSEcCtD
Cefdinir—Headache—Prednisone—prostate cancer	6.52e-05	0.000231	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.5e-05	0.00023	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.46e-05	0.000979	CbGpPWpGaD
Cefdinir—Constipation—Doxorubicin—prostate cancer	6.44e-05	0.000228	CcSEcCtD
Cefdinir—Abdominal pain—Epirubicin—prostate cancer	6.43e-05	0.000228	CcSEcCtD
Cefdinir—Body temperature increased—Epirubicin—prostate cancer	6.43e-05	0.000228	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.35e-05	0.000963	CbGpPWpGaD
Cefdinir—Nausea—Prednisone—prostate cancer	6.18e-05	0.000219	CcSEcCtD
Cefdinir—Gastrointestinal pain—Doxorubicin—prostate cancer	6.16e-05	0.000218	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	6.15e-05	0.000932	CbGpPWpGaD
Cefdinir—Hypersensitivity—Epirubicin—prostate cancer	5.99e-05	0.000212	CcSEcCtD
Cefdinir—Abdominal pain—Doxorubicin—prostate cancer	5.95e-05	0.000211	CcSEcCtD
Cefdinir—Body temperature increased—Doxorubicin—prostate cancer	5.95e-05	0.000211	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—RXRA—prostate cancer	5.85e-05	0.000887	CbGpPWpGaD
Cefdinir—Asthenia—Epirubicin—prostate cancer	5.84e-05	0.000207	CcSEcCtD
Cefdinir—Pruritus—Epirubicin—prostate cancer	5.76e-05	0.000204	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	5.71e-05	0.000865	CbGpPWpGaD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—NCOA1—prostate cancer	5.61e-05	0.000851	CbGpPWpGaD
Cefdinir—Diarrhoea—Epirubicin—prostate cancer	5.57e-05	0.000197	CcSEcCtD
Cefdinir—Hypersensitivity—Doxorubicin—prostate cancer	5.55e-05	0.000197	CcSEcCtD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—RXRA—prostate cancer	5.43e-05	0.000823	CbGpPWpGaD
Cefdinir—Asthenia—Doxorubicin—prostate cancer	5.4e-05	0.000191	CcSEcCtD
Cefdinir—Dizziness—Epirubicin—prostate cancer	5.38e-05	0.000191	CcSEcCtD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—RXRA—prostate cancer	5.34e-05	0.000809	CbGpPWpGaD
Cefdinir—Pruritus—Doxorubicin—prostate cancer	5.33e-05	0.000189	CcSEcCtD
Cefdinir—Vomiting—Epirubicin—prostate cancer	5.17e-05	0.000183	CcSEcCtD
Cefdinir—Diarrhoea—Doxorubicin—prostate cancer	5.15e-05	0.000182	CcSEcCtD
Cefdinir—Rash—Epirubicin—prostate cancer	5.13e-05	0.000182	CcSEcCtD
Cefdinir—Dermatitis—Epirubicin—prostate cancer	5.13e-05	0.000182	CcSEcCtD
Cefdinir—Headache—Epirubicin—prostate cancer	5.1e-05	0.000181	CcSEcCtD
Cefdinir—Dizziness—Doxorubicin—prostate cancer	4.98e-05	0.000176	CcSEcCtD
Cefdinir—Nausea—Epirubicin—prostate cancer	4.83e-05	0.000171	CcSEcCtD
Cefdinir—Vomiting—Doxorubicin—prostate cancer	4.79e-05	0.00017	CcSEcCtD
Cefdinir—Rash—Doxorubicin—prostate cancer	4.75e-05	0.000168	CcSEcCtD
Cefdinir—Dermatitis—Doxorubicin—prostate cancer	4.74e-05	0.000168	CcSEcCtD
Cefdinir—Headache—Doxorubicin—prostate cancer	4.72e-05	0.000167	CcSEcCtD
Cefdinir—Nausea—Doxorubicin—prostate cancer	4.47e-05	0.000158	CcSEcCtD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—PPARA—prostate cancer	4.47e-05	0.000677	CbGpPWpGaD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—PPARA—prostate cancer	4.15e-05	0.000629	CbGpPWpGaD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—PPARA—prostate cancer	4.08e-05	0.000618	CbGpPWpGaD
Cefdinir—SLC15A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.55e-05	0.000538	CbGpPWpGaD
Cefdinir—SLC15A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.29e-05	0.000499	CbGpPWpGaD
Cefdinir—SLC22A5—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.24e-05	0.000491	CbGpPWpGaD
